首页> Chinese clinical oncology> From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cance.

From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cance.

导出 LinkOut

翻译打印收藏纠错

第一作者： Sophie,Doisneau-Sixou

第一单位： Breast Center, Department of Obstetrics & Gynecology, and Comprehensive Cancer Center, University of Munich, Munich, Germany. Faculty of Pharmacy, University Paul Sabatier Toulouse III, Toulouse, France.

作者： Sophie,Doisneau-Sixou ^[1] ; Nadia,Harbeck ^[2]

作者单位： Breast Center, Department of Obstetrics & Gynecology, and Comprehensive Cancer Center, University of Munich, Munich, Germany. Faculty of Pharmacy, University Paul Sabatier Toulouse III, Toulouse, France. ^[1] Faculty of Pharmacy, University Paul Sabatier Toulouse III, Toulouse, France. ^[2]

关键词 Breast cancer clinical trial driver mutation druggable gene high-throughput technology

DOI 10.3978/j.issn.2304-3865.2014.05.15

PMID 25841412

发布时间 2015-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览33

Chinese clinical oncology

2014年3卷2期

16页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览33

点击下载本期目录封面

Chinese clinical oncology

2014年3卷2期

16页

检索历史清除

From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cance.

Chinese clinical oncology

相似文献

同项目论文

Chinese clinical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cance.

Chinese clinical oncology

相似文献

同项目论文

Chinese clinical oncology

相关期刊

检索历史清除